1361 Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity.
https://www.science.org/doi/10.1126/scitranslmed.abm7853
1360 Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
https://www.nature.com/articles/s41586-021-04385-3
1359 Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis.
https://www.pnas.org/content/119/8/e2116271119
1358 Intestinal group 3 innate lymphoid cells have memory-like properties after bacterial infection that contribute to long-term mucosal defense.
https://www.science.org/doi/10.1126/science.aaz8777
1357 Antibody structure prediction using interpretable deep learning.
https://www.cell.com/patterns/fulltext/S2666-3899(21)00280-4
1356 Ex vivo enzymatic treatment converts blood type A donor lungs into universal blood type lungs.
https://www.science.org/doi/10.1126/scitranslmed.abm7190
1355 A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates.
https://www.science.org/doi/10.1126/scitranslmed.abi5735
1354 Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain.
https://www.science.org/doi/10.1126/scitranslmed.aax7706
1353 Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.
https://www.nature.com/articles/s41586-021-04390-6
1352 Engineered human antibodies for the opsonization and killing of Staphylococcus aureus.
https://www.pnas.org/content/119/4/e2114478119
|
